Your browser doesn't support javascript.
loading
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Wang, Daniel Y; Eroglu, Zeynep; Ozgun, Alpaslan; Leger, Paul D; Zhao, Shilin; Ye, Fei; Luke, Jason J; Joseph, Richard W; Haq, Rizwan; Ott, Patrick A; Hodi, F Stephen; Sosman, Jeffrey A; Johnson, Douglas B; Buchbinder, Elizabeth I.
Afiliación
  • Wang DY; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Eroglu Z; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
  • Ozgun A; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
  • Leger PD; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Zhao S; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Luke JJ; Department of Medicine, University of Chicago, Chicago, Illinois.
  • Joseph RW; Department of Medicine, Mayo Clinic Florida, Jacksonville, Florida.
  • Haq R; Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Ott PA; Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Hodi FS; Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts.
  • Sosman JA; Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois.
  • Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. douglas.b.johnson@vanderbilt.edu elizabeth_buchbinder@dfci.harvard.edu.
  • Buchbinder EI; Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts. douglas.b.johnson@vanderbilt.edu elizabeth_buchbinder@dfci.harvard.edu.
Cancer Immunol Res ; 5(5): 357-362, 2017 05.
Article en En | MEDLINE | ID: mdl-28396509
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos / Melanoma / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Res Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Antineoplásicos Inmunológicos / Melanoma / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Res Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos